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Introduction
Delays to inpatient discharge from the hospital for medically ready patients are 
associated with a large cost, both economically to the overall healthcare system and to 
the individual patient. Several studies show that at a given institution, these unnecessary 
hospitalization days can cost upwards of millions of dollars, not to mention the 
additional risk of exposing patients to hospital-acquired infections.1,2 The reasons for 
these delays are many and varied, but include individual complex social issues, ride 
availability, poor follow-up, or an unprepared disposition plan. 
At our institution (Stanford Health Care), we have observed that one contributing factor 
is that prescribed discharge medications are not yet approved by a patient’s health insur-
ance company at the time of discharge. Stanford has a diverse patient population with 
many patients relying on state or federally funded government insurance programs, 
which have limited drug formularies. Depending on a patient’s insurance, certain 
medications need a prior authorization (PA) in order to be approved and affordable. This 
process can take between hours to days and, if started at the time a patient is medically 
ready for discharge, can delay the patient’s ability to safely leave the hospital. 
It has been shown that medications requiring a PA take significantly longer to fill (one 
study involved a median time of four days longer) than those that do not.3 Inability to 
access medications upon discharge can negatively impact adherence, increasing risk 
of post-discharge adverse drug events.4 Therefore, discharges are often delayed while 
waiting for medications to receive prior authorization approval. 
Based on our experience, there are no studies that evaluate delays due to discharge 
medications needing to undergo the PA process. Thus, in our pilot study, we both 
aim to define the scope of this problem by surveying resident physicians as well as 
provide an intervention to identify earlier medications that will need to undergo a PA 
process. Pharmacy-led interventions in processing PAs have resulted in a statistically 
significant benefit in improving time to PA approval, fill, and pickup.5 Therefore, in our 
intervention, we utilize a specialized “transitions of care” (TOC) pharmacist to analyze 
the medications of patients who are predicted to be discharged and alert the medical 
team of potential medications that may need PA approval, with the intended effect that 
this process will start long before a patient is actually discharged.
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Methods
Setting
This study took place at Stanford Health 
Care, a teaching academic center located 
in Stanford, California. Stanford Hospital 
is a 613-bed, urban medical center. This 
intervention involved all five house-staff 
inpatient general internal medicine wards 
teams that are staffed by two interns, one 
resident, and one attending, as well as one 
to two medical students. The university 
institutional review board notice of deter-
mination waived review for this study 
since it was classified as quality improve-
ment. The purpose of this project was to 
optimize and improve local care.
Survey 
Prior to implementing our intervention, 
a nine-question survey was created and 
electronically distributed to the Stanford 
Internal Medicine Residency program 
using Stanford University Qualtrics 
software (July 2015). Questions assessed 
the frequency of delays to discharge 
related to medications and knowledge of 
formulary information. 
Intervention
Of the five teaching Internal Medicine 
teams at our institution, two were 
randomized into our intervention and 
the remaining three served as control 
teams. The intervention teams met daily 
with a TOC pharmacist to review the 
medication lists of upcoming discharges, 
which were defined as patients predicted 
to be discharged within 24-48 hours. 
The TOC pharmacist would screen the 
patient’s medication list for medications 
that require a PA; call the outpatient 
pharmacies to confirm medication stock, 
insurance coverage and need for a PA; and 
initiate the processing of the claim. This 
information was then forwarded to the 
medical team. If a patient did not leave 
by the predicted discharge time, the TOC 
pharmacist would ask the team to identify 
a reason for the delayed discharge. 
The control teams met daily with a resi-
dent physician and were similarly queried 
about identifying upcoming discharges. 
However, medications were not reviewed 
with the team and the medical team was 
not alerted of any medications that may 
need a PA approval. If a patient did not 
leave by the predicted discharge time, the 
medical team would be asked to identify a 
reason for the delayed discharge.
A PA list (Figure 1) was created by 
TOC pharmacists at our institution as 
a reference tool to identify medications 
frequently requiring PA. The TOC 
pharmacist in our intervention was 
able to defer to this list to guide 
recommendations. This list was also 
provided to the control group so that 
all five medical teams had the same 
information available. However, only 
the intervention team had daily rounds 
with the TOC pharmacist to screen the 
patient medication list and intervene in 
the PA process. 
Statistical Analysis
Patient data from the intervention and 
from their medical chart were recorded in 
Microsoft Excel. Data collected included 
the patient’s predicted and actual discharge 
date, length of stay (LOS), number of 
PAs for discharge medications needed, 
insurance company, number of days 
delayed, and reason for delayed discharge. 
Comparisons between the intervention 
and control teams for the two primary 
outcomes (delayed discharge by 24 hours 
and number of days delayed for discharge) 
were statistically analyzed with a Student’s 
t-test. Mean length of stay was also 
compared using a Student's t-test. Both the 
intervention and control comparisons were 
completed concurrently over a continuous 
three-week period. 
Ethical Considerations
There were no identifiable ethical 
considerations or conflicts of interest.
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Results
Survey
A total of 72 resident physicians 
responded to the survey with a response 
rate of approximately 63%. The over-
whelming majority (94%) had responded 
that they had experienced delays in 
discharge due to medication problems, 
with a significant portion attributed to 
not having PA approval in time (Table 1). 
Additionally, 71% of residents responded 
that they had limited knowledge of the 
Stanford insurance formulary (Table 1). 
Residents were also asked to identify 
medications likely to require a PA 
and were assessed on their ability to 
correctly identify where to find insurance 
information within the electronic health 
record. The responses overwhelmingly 
indicated little understanding of 
medication formularies, with 98% unable 
to correctly identify the number of 
medications covered by MediCal.
Intervention
A total of 66 patients were involved in  
the intervention arm and 98 patients in 
the control arm, with balanced demo-
graphics and insurance profiles (Table 2). 
In the intervention arm, there were 20 
discharge prescriptions needing PA,  
while in the control arm there were  
25 discharge prescriptions needing PA 
(Table 2). The most common medications 
requiring PA were oral vancomycin 
(n=5) and enoxaparin (n=4). Figure 2 
highlights the breakdown of medications 
requiring PA in both the control and 
intervention groups. Of these patients 
discharged with a medication requiring a 
PA, 4/25 patients were identified from the 
control teams who experienced greater 
than 24-hour delays to discharge due to 
medications not having a PA approval 
available at the time of discharge, 
compared to 0/20 patients identified on 
the intervention teams (P=0.06). When 
comparing the number of extra hospital 
Questions Responses, n (%)
On average, how often have you 
experienced delays in discharge due 
to medication? (n=72)
Never: 
4 (6)
1-2 times per year: 
8 (11)
1-2 times per month: 
39 (54)
1-2 times per week: 
16 (22)
More than 2 times per week:
5 (7)
For the previous question, about 
what percentage were due to not 
having prior authorization? 
(n=68)
0%: 
7 (10)
25%: 
20 (29)
50%: 
18 (27)
75-100%: 
13 (19)
Not sure: 
10 (15)
On a scale of 1-5 (5 being the 
most confident), how confident 
are you in your knowledge of the 
insurance formulary information 
displayed in Epic (eg, the "tiers" 
and "preferences" displayed when 
prescribing discharge medications)? 
(n=72)
1-Not confident at all: 
51 (71)
2-Slightly confident: 
13 (18)
3-Some confidence: 
7 (10)
4-Confident: 
1 (1)
5-Very confident: 
0 (0)
On average, how many days before 
discharge do you place discharge 
medication orders? 
(n=72)
At the time of discharge: 
32 (44)
1 day prior: 
36 (50)
2 days prior: 4 (6)
Please indicate your level of training. 
(n=72)
First-year resident: 
20 (28)
Second-year resident: 
29 (40)
Third-year resident: 
23 (32)
Table 1.  Survey questions distributed to resident physicians and responses
The majority of respondents experienced medication-related delays to discharge, many of which were due to not having PA approval. Of 115 residents surveyed, 72 residents responded for a 63% response rate.
days caused by delayed discharges 
secondary to unsecured PAs per number 
of potential discharges, there were six 
days of extra hospitalization for patients 
from the control group out of 27 potential 
discharges compared to zero extra days 
for patients from the intervention side 
out of 20 potential discharges (P=0.02).
LOS for the intervention and control 
teams was not significantly different  
(6.3 vs 5.8 days, respectively; P=0.37).
Discussion;
Among internal medicine residents at 
our institution, our survey showed that 
it was not uncommon that discharges 
were being delayed due to discharge 
medications not having a completed 
PA. We speculate that this could be 
associated with late placement of 
discharge prescriptions. If physicians do 
not know a PA is required for a certain 
medication, they may not place early 
Original Research
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discharge medication orders and start 
the PA process earlier, thus possibly 
delaying discharge. It has been shown 
that anticipatory discharge orders, 
in which discharge orders including 
prescriptions are placed more than 24 
hours before discharge, decreases LOS.6
Interestingly, our survey also showed a 
dearth of knowledge regarding medical 
coverage and insurance formularies 
among resident physicians. Results 
suggest that consideration of patient 
insurance and formularies are not 
necessarily taken into consideration 
when prescribing. This may contribute to 
medication-related access barriers. This 
is an opportunity at our institution to 
provide education to prescribers about 
formulary considerations and enhance 
available resources, including making 
our PA list (Figure 1) widely available 
while encouraging prescribers to seek a 
pharmacist when needed.
Our intervention involves a third 
party knowledgeable about medication 
coverage earlier in the discharge process. 
Collaborating with the TOC pharmacist 
allows prescribers to identify and resolve 
PAs in anticipation of discharge, as well as 
improve prescribing in compliance with 
patient-specific insurance formularies 
by facilitating drug substitutions when 
appropriate. By utilizing a specialized 
TOC pharmacist, we were able to identify 
discharge medications needing PA well 
before discharge, saving six days of 
unnecessary hospitalization compared 
to control in a three-week time span. 
Despite this, LOS between the two groups 
was not significantly different as expected. 
Many different factors determine LOS 
so it is possible that one confounder or 
outlier disproportionately affected one 
group of our relatively small sample size. 
While a pharmacy technician could also 
be helpful in identifying medications 
requiring PA, pharmacists are also able to 
suggest therapeutic alternatives, which are 
beyond the scope of pharmacy technicians. 
Additionally, this practice was incor-
porated into the workflow of our TOC 
pharmacists who already see patients at 
discharge. Therefore, there were no addi-
tional costs associated. This did support 
the need for collaborating with pharma-
cists in discharge planning. While 
...our survey also showed 
a dearth of knowledge 
regarding medical 
coverage and insurance 
formularies among 
resident physicians. 
Results suggest that 
consideration of patient 
insurance and formularies 
are not necessarily taken 
into consideration when 
prescribing.
Characteristic, n (%) Intervention Control P-value
Number of patients, n 66 98 -
Female 31 (47) 48 (49) 0.88
Average LOS, days 6.3 5.8 0.37
Number of patients with primary Medicare insurance 20 (30) 27 (28) 0.77
Number of patients with primary MediCal insurance 8 (12) 17 (17) 0.43
Number of patients with medications needing PA 20 (30) 25 (26) 0.61
Number of patients with delayed discharges due to unsecured PAs/number 
of patients with medications needing a PA
0/20 (0) 4/25 (16) 0.06
Number of extra hospital days from delayed discharges due to unsecured 
PAs/number of potential discharges among patients with medications 
needing a PA
0/20 (0) 6/27 (22) 0.02
LOS, length of stay; PA, prior authorization.
Days of unnecessary hospitalization due to unsecured prior authorizations are significantly greater in the control group.
Table 2. Patient characteristics and specific medications requiring PA
84     cjhp     California Journal of Health-System Pharmacy  May/June 2018
Original Research
Figure 1. PA list
To better help transition patients out of the hospital, we would like to provide this list for our prescribers to be 
alerted and to be looking for medications that are known to be troublesome in the outpatient setting (prior 
authorization, step therapy, TAR, high cost, etc) . DISCLAIMER: THIS MEDICATION LIST IS ONLY A REFERENCE 
AND MAY NOT BE COMPREHENSIVE/ 
Diabetes• • Lantus Solostar (glargine) Transplant • Prograf (tacrolimus) 
• Kwikpen (lispro/aspart) medications • Rapamune (sirolimus) 
• Ensure all pen products are covered • Cellcept/Myfortic 
Please remember to prescribe test (mycophenolate) 
strips, lancets, lancing device, and/or . Cyclosporine 
control solutions for their home • Mepron (atovaquone) 
diabetic glucometers. 
GU/GI • Xifaxan (rifaximin) Inhalers• • Advair • Asmanex 
• Rowasa (mesalamine enema) • Qvar • Xopenex 
• Combivent • Breo Ellipta, 
• Pulmicort etc . 
Antibiotics • Zyvox (linezolid) Pulmonary • Revatio (sildenafil) 
• Vantin (cefpodoxime) Hypertension • Letairis (ambrisentan) 
• Levaquin (levofloxacin) • Tracleer (bosentan) 
• vancomycin oral (Vancocin) : • Adcirca (tadalafil) 
capsules/solution • Ventavis (iloprost) 
0 vancomycin solution requires a • Tyvaso (treprostinil inhalled) 
compounding pharmacy • Remodulin (treprostinil IV/SQ) 
. Vfend (voriconazole) • Flolan (epoprostenol) 
• Noxafil (posaconazole) • Veletri (epoprostenol), etc . 
Anti platelets • Plavix (clopidogrel") Anticoagulants • All novel anticoagulants• 
• Brilinta (ticagrelor) 0 Pradaxa (dabigatran) 
• Effient (prasugrel) 0 Eliquis (apixaban) 
Others • Lidoderm patches 0 Xarelto (rivaroxaban) 
• lnjectables 
• Growth factors : Neupogen 
(filgrastim), Neulasta 0 Lovenox (enoxaparin) 
(pegfilgrastim), Epogen/Procrit 0 Arixtra (fondaparinux) 
(epoetin alpha), etc 0 Fragmin (dalteparin) 
• Nimodipine (Nimotop) Antiarrhythmics • Multaq (dronedarone) 
• Oral Chemotherapy Agents: • Always check stock with 
Dasatanib, lmmatanib, sprycel, pharmacy for older 
Gleevec, etc. antiarrhythmics. 
Please remember to prescribe syringes 
and/or needles for all injectables if 
not pre-filled. 
Please seek prior authorization for all IV medications {eg. Cubicin (daptomycin), Te/Iara {ceftaroline), etc.} 
Special formulations (eg. oral disintegrating tablets (ODT), wafers), may have higher costs. 
If patient is already on a medication before com ing to the hospital, most likely the medication is already covered! 
*Most insurance have a preferred formulary agent. Please refer if needing assistance. 
"State of CA, Medi-Cal on ly 
Prepared by Transitions of Care Pharmacy Connie Elejade, PharmD, BCPS, and Noah Fang, PharmD, BCPS 
in collaboration with Case Management Team 
Last Rev 1/2014 
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this required a pharmacist to dedicate a 
small amount of time each day to screen 
patient medication lists in anticipation of 
discharge barriers, the anticipated benefit 
is reduction of timely delays. 
The results of our study prompted 
initiation of daily discharge rounds at our 
institution that included the participation 
of physicians, pharmacists, social workers, 
case managers, and other care providers 
to anticipate and resolve discharge needs 
in advance of patients returning home. 
Limitations of this study include a 
relatively short timeframe for the 
intervention (three weeks) as well as a 
relatively small sample size from a single 
academic medical center. This may have 
contributed to the lack of statistically 
significant data. However, this study 
highlights the need for addressing PAs in 
advance of hospital discharge to reduce 
medication-related barriers and their 
potential consequences.
In summary, these results suggest that 
unnecessary hospitalization days due 
to the need for PA can be saved with 
standardized screening for the need 
for PAs earlier than the discharge 
date.  Future research would benefit 
from further evaluating the impact of 
pharmacist involvement in the discharge 
planning process to reduce LOS, reduce 
health care-associated costs, and improve 
health care-related outcomes. This would 
further support including a pharmacist 
on every medical team or partnering with 
an outside outpatient pharmacy that can 
expedite and complete all PA processes 
for discharging patients.
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Medications requiring PA
Intervention Group Control Group
Figure 2. Medications requiring PA
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Conclusions
We are the first, to our knowledge, to 
show that delays to discharge due to 
unsecured PA of discharge medications 
is a widespread problem and that earlier 
identification of these medications can 
reduce unnecessary delays due to the 
need to complete PAs before discharge. 
Our study supports the improvement of 
processes to screen for discharge medi-
cation lists prior to the day of discharge. 
Utilizing pharmacists in the screening 
process is an effective method to achieve 
this goal. o
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